H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $75 from $72, keeping a Buy rating on the shares.

Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now?

An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals.

The rating update came after Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results.

The analyst told investors in a research note that Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its fiscal 2025 guidance for the third time this year following another quarter of solid results.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported its fiscal Q2 2025 results on August 5, with total revenue increasing 41% year-over-year to $326 million and royalty revenue growing 65% year-over-year to $206 million.

Net income for the quarter rose 77% year-over-year to $165 million, while adjusted EBITDA increased 65^ year-over-year to $226 million.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology.

They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HALO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.